Cargando…
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
AIMS: Soticlestat, a first‐in‐class inhibitor of cholesterol 24‐hydroxylase (also known as cytochrome P450 46A1), is currently in development for the treatment of developmental and epileptic encephalopathies. Here, we report safety, tolerability, pharmacokinetic and pharmacodynamic outcomes from a p...
Autores principales: | Wang, Shining, Chen, Grace, Merlo Pich, Emilio, Affinito, John, Cwik, Michael, Faessel, Hélène M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305210/ https://www.ncbi.nlm.nih.gov/pubmed/35001412 http://dx.doi.org/10.1111/bcp.15225 |
Ejemplares similares
-
Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
por: Wang, Shining, et al.
Publicado: (2021) -
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
por: Peterschmitt, M. Judith, et al.
Publicado: (2020) -
Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015) -
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
por: Family, Neiloufar, et al.
Publicado: (2019) -
Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers
por: Ramanathan, Srini, et al.
Publicado: (2016)